Half-dose oxytocin

Phase 3Small molecule

NNorthwestern University

Half-dose oxytocin is one of 5 small molecule programs targeting Oxytocin. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OxytocinRecruiting

OxytocinPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Oxytocin

#DrugCompanyPhaseTrials

Pitocin

RRetrophin

Approved

108 2

Intranasal Oxytocin

UUniversity of Electronic Science and Technology of China

Phase 2

18 3

Half-dose oxytocin

NNorthwestern University

Phase 3

2 4

Pitressin

AAultman Health Foundation

Preclinical

1 5

Norethindrone Acetate-Ethinyl Estradiol

EElizabeth Austen Lawson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxytocin2 trials

Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

Terminated·NNorthwestern University·N/A·NCT02121184·172 enrolled

Oxytocin and Fetal Heart Rate Changes

Recruiting·UUnyime Ituk·Phase 4·NCT03232918·730 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Half-dose oxytocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Half-dose oxytocin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Half-dose oxytocin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNorthwestern University

Half-dose oxytocin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oxytocin2 trials

References

Drug Info

Quick Facts

Related News